Market research
TGKQ.F Precipio, Inc
F EUR Healthcare
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 367K
- P/E ratio
- Not available
- Analyst target
- 7
- Dividend yield
- 0.0%
- Beta
- 2.04
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- Not available
- Market cap
- 367K
- P/E ratio
- Not available
- Analyst target
- 7
- Dividend yield
- 0.0%
- Beta
- 2.04
About
About Precipio, Inc
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.
Research context
Precipio, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the TGKQ.F discussion.
5 years, 6 months ago
Precipio, Inc is currently in a long term uptrend where the price is trading 14.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.3.
Precipio, Inc's total revenue rose by 182.1% to $2M since the same quarter in the previous year.
Its net income has increased by 50.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 31.0% to $-1M since the same quarter in the previous year.
Based on the above factors, Precipio, Inc gets an overall score of 5/5.